Remarks

The specification is amended to add a paragraph reciting related applications and to conform with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures. No new matter is introduced. No amendments are made to the claims. No amendments are made to the figures.

The specification is amended to add a paragraph reciting related applications. This information was included with the original transmittal letter that accompanied the request to begin national procedures under 35 U.S.C. 371(f), filed on July 23, 1999.

The specification is also amended to conform with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, as specified in the Office Action dated July 31, 2001. Applicants thank the Examiner for the opportunity to discuss with her the requirements and the manner of amending the specification to satisfy the requirements. Specifically, SEQ ID NO: identifiers are associated with particular sequences disclosed in the specification. In addition, minor typographical corrections are made to correct obvious misspellings and errors in capitalization and punctuation.

A substitute Sequence Listing is also submitted herewith, incorporating the amino acid sequence SIINFEKL as SEQ ID NO: 3. This amino acid sequence, which appears at page 16, line 14 and at page 24, line 10 of the specification, was not previously assigned a SEQ ID NO or listed in the Sequence Listing. The substitute Sequence Listing incorporates this amino acid sequence by substituting it for a duplicated nucleotide sequence originally listed as SEQ ID NO: 3, where the latter nucleotide sequence was identical to the nucleotide sequence listed as SEQ ID NO: 4. The effect of this substitution is two-fold: it removes an inadvertent duplication in the sequence listing, and it incorporates, as required under 37 C.F.R. 1.821, the amino acid sequence disclosed in the specification. The number of sequences in the substitute Sequence Listing is the same as in the previous Sequence Listing.

It is believed that the application as amended is now in conformity with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, and that the claims are in condition for allowance. Favorable action is earnestly solicited. If for any reason the examiner has any question or would require further information, she is encouraged to contact the Applicant's representative at the number presented below.

Respectfully submitted,

Alan W. Steele
Registration No. 45,128
Wolf, Greenfield and Sacks, P.C.
600 Atlantic Ave.
Boston, MA 02210
617/720-3500
Fax/617/720-2441

C1041/7005 (AWS)
October 17, 2001
X 08/31/2001
XX 01/31/2002